<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01957891</url>
  </required_header>
  <id_info>
    <org_study_id>QATP2552</org_study_id>
    <nct_id>NCT01957891</nct_id>
  </id_info>
  <brief_title>Hypoxia at Multiple Wavelengths of Light</brief_title>
  <official_title>Effect of Induced Hypoxia at Multiple Wavelengths</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nonin Medical, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nonin Medical, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the effect of progressive, incremental hypoxia at&#xD;
      multiple wavelengths of light.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No additional information is required.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the effect of progressive, incremental hypoxia at multiple wavelengths of light</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Hypoxia in Healthy Individuals</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is between 18 and 35 years of age&#xD;
&#xD;
          -  Is American Society Anesthesiologist status 1&#xD;
&#xD;
          -  Has a BMI between 18 and 30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently taking any medications other than birth control pills&#xD;
&#xD;
          -  Has participate in an investigational drug study within one month prior to the start&#xD;
             of the study&#xD;
&#xD;
          -  Fails the Allen's Test to confirm patency of the colateral artery&#xD;
&#xD;
          -  Subject is female with a positive pregnancy test, or is female and is unwilling to use&#xD;
             effective birth control between the time of screening and study termination&#xD;
&#xD;
          -  Has a positive urine continine or drug test&#xD;
&#xD;
          -  Has an reported allergy to Lidocaine&#xD;
&#xD;
          -  Has anemia or other hemoglobinopathy&#xD;
&#xD;
          -  Has a room air saturation less than 95% by pulse oximetry&#xD;
&#xD;
          -  Has an abnormal EKG&#xD;
&#xD;
          -  Has an abnormal pulmonary function test via spirometry&#xD;
&#xD;
          -  Is intolerant to a breathing mask apparatus&#xD;
&#xD;
          -  Has a COHb greater than 3%, or MetHb greater than 2%&#xD;
&#xD;
          -  Has another condition, which in the opinion of the principle investigator would not be&#xD;
             suitable for participation in the study&#xD;
&#xD;
          -  Is unwilling or unable to provide informed consent or comply with the study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David MacLeod, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HPPL Duke Univeristy</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>September 19, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>March 6, 2014</last_update_submitted>
  <last_update_submitted_qc>March 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoxia</keyword>
  <keyword>Multiple wavelengths</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

